CYP51A1 and liver failure: Therefore, we propose to include selected CYP51A1 variants into personalized diagnostics panel for evaluating risks for pediatric cataract, neonatal hepatic failure, global developmental delay, azole susceptibility, and cardiovascular and metabolic diseases.